Esri Brings Powerful Mapping Technology to Everyone with New Storytelling Tool
20.4.2022 15:00:00 EEST | Business Wire | Press release
Capturing and sharing life's experiences today often requires multiple platforms and tools, which can result in disjointed storytelling. To serve creators' needs to control their dynamic, interactive narratives in one place, Esri, the global leader in location intelligence, today released StoryMaps, a powerful, personal storytelling tool. The product extends Esri's creative capabilities to anyone who wants to tell their story and share it.
Using Esri's mapping technology, this new software brings the geographic approach to any content that creators are passionate about. From documenting their ancestral journey to capturing aspects of daily life or planning a first big post-pandemic trip, StoryMaps helps capture life's moments in a way worthy of those experiences.
"At Esri, we understand that sharing stories is a part of life, that everyone is a storyteller," said Jack Dangermond, Esri founder and president. "Every moment and memory we treasure is connected to a specific location, which is why we're making it easier to transport people anywhere in the world through richer storytelling."
Esri allows authors to control their narratives with built-in privacy to protect data and automatic content ownership and create them in versatile ways that reflect the experiences themselves. People can creatively combine text with multimedia like images, videos, audio, and links to easily share their personal experiences, hobbies, family history, ancestry, portfolios, travels, and more.
The National Geographic Society (NGS)—which for more than 130 years has been illuminating and protecting the world through science, exploration, education, and storytelling—is partnering with Esri to bring StoryMaps to its members.
"The National Geographic Society has a long legacy of storytelling, and it remains fundamental to our mission work today as we further our understanding of our planet and each other," said Jill Tiefenthaler, National Geographic Society chief executive officer. "Our partnership with Esri enriches this legacy, empowering our members to share their unique stories and experiences through this innovative geospatial tool."
Esri designed StoryMaps to enable everyone with varying digital skills to create custom content without requiring cartography or web design experience. StoryMaps allows authors to
- Build a story in one place. Make versatile stories of any length using your assets (text, photos, videos, audio, etc.) or leverage Unsplash for ready-to-use images.
- Publish and share your story with any audience. Make a private journal, create a shareable unlisted link for family and friends, or publish on all popular social media platforms. Authors can also embed stories on websites and blogs.
- Add custom interactive maps. Bring readers along your journey by adding a map with graphics and pop-ups or create a thematic map to visualize trends.
- Incorporate engaging features. Display content in different ways using flexible components including a timeline, image gallery, swipe, and quotes. All content can be organized into collections that act like folders.
- Customize the look. Choose from built-in themes or customize a design with a different font, color, and layout options.
- Keep it current. Update and publish stories easily with new features and capabilities every two weeks. Future features will include geo-ready data from wearables to show off your latest outdoor activities.
A free basic plan is available with essential storytelling capabilities to ensure all storytellers have access at any time. When new users sign up, they have free access to Premium features with enhanced storytelling capabilities for the first 30 days. After, they can decide to purchase a monthly or annual Premium subscription to StoryMaps at $10 or $100, respectively, or downgrade to the free, basic storytelling option.
To explore StoryMaps, read stories, and get started, visit storymaps.com.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, StoryMaps, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005532/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email:
jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
